• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

A Discussion on Managing and Treating Type 2 Diabetes

Podcast

As a progressive condition, diabetes presents an ongoing challenge for physicians to provide adequate control of patients’ disease, and new agents with novel mechanisms of action help reduce the burden in the management of diabetes.

As a progressive condition, diabetes presents an ongoing challenge for physicians to provide adequate control of patients’ disease, and new agents with novel mechanisms of action help reduce the burden in the management of diabetes.

In a recent Peer Exchange discussion, Peter Salgo, MD, of Columbia University College of Physicians and Surgeons and NewYork-Presbyterian Hospital, led a discussion on novel agents and their role in treating patients with and without cardiovascular disease. On the panel was Om Ganda, MD, of Joslin Diabetes Center; Jim Kenney of JTKenney, a managed care consulting practice; and Helena Rodbard, MD, FACP, MACE, past president of the American College of Endocrinology and past president of the American Association of Clinical Endocrinologists.

Here, you can listen to part of the discussion.

iTunes

TuneIn

Stitcher

Spotify

Listen above or through one of these podcast services:

Watch the full discussion.

Related Videos
Sudipto Mukherjee, MD, PhD, MPH, hematology and medical oncology, Cleveland Clinic
Video 12 - "Key Considerations for Treating Patients Diagnosed With CLL and SLL"
Video 11 - "Optimizing BTKi Treatment Strategies"
Video 13 - "Other Clinical Considerations in Demodex Blepharitis Treatment"
Video 12 - "Cost-Effective Medication Access in Demodex Blepharitis Management"
Video 10 - "Patient Education Drives BTK Inhibitor Treatment Adherence"
Video 11 - "Understanding Demodex Blepharitis Pathogenesis"
Video 9 - "Economic Burden Is Associated With BTK Inhibitor Use"
Related Content
© 2024 MJH Life Sciences
AJMC®
All rights reserved.